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Abstract
Background: We report our experience with patients who received re-irradiation to the head and neck area for
locoregional recurrences (LRR) or second primaries (SP) in a previously irradiated field.
Methods: We reviewed 27 consecutive patients with a diagnosis of LRR or SP head and neck carcinoma treated
with a second course of radiotherapy between April 2004 and July 2012. The main outcome measures were local
control, overall survival, and complications. The results are expressed as actuarial values using the Kaplan–Meier
estimates.
Results: The median follow-up time was 24.7 months (range: 11 days–79.3 months). There were 23 males and four
females with a median age of 61 years (range: 40–87 years). The actuarial overall survival rates at 1, 2, and 5 years
were 77, 59, and 57 %, respectively. The actuarial local control rate was 80, 52, and 52 % at 1, 2, and 5 years, respectively.
Three patients developed systemic metastases. The rate of grade 3 toxicity was 26 %, and that of grade 4 toxicity
was 3 %. There were two treatment-related deaths (grade 5 toxicity).
Conclusions: Continuous course re-irradiation in patients with LRR or SP head and neck cancer is feasible with
acceptable toxicity. With current encouraging rates of local control and overall survival, this option should be
discussed with patients who have few alternative therapeutic options.
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Background
Surgical resection is typically considered the modality of
choice in patients with locoregional recurrences (LRR)
or second primary (SP) head and neck cancer who were
previously treated with a full dose of radiation therapy
[1]. Historically, patients who were deemed to have
unresectable tumors, because of tumor location, extent,
or medical comorbidities, were referred for palliative
chemotherapy. However, the response rates achieved
with chemotherapy for these patients ranged between 10
and 40 % [2]. In the last decade, re-irradiation (RI) has
begun to gain conceptual acceptance, as experimental
and clinical studies have demonstrated that high-dose RI
can be administered with reasonable success and accept-
able complication rates.
The management of LRR or SP head and neck cancer
in patients who were previously treated with a full dose
of irradiation remains a clinical challenge. The difficulty
arises from the possibility of serious side effects follow-
ing RI [3, 4]. Some of these toxicities, such as carotid
rupture, fistula, or bleeding, can be life-threatening. In
addition, other serious but non-life-threatening side ef-
fects can occur – for example, osteonecrosis, soft tissue
fibrosis, carotid stenosis, severe xerostomia, and trismus.
In spite of these complications, accumulated data from
different centers [5–7] showed increased local control and
survival in patients treated with a tri-modality approach,
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including surgery followed by RI and chemotherapy (if
indicated), over single modality or chemotherapy alone.
Reasonable survival has been reported with primary RI
alone, with a median survival of 10 months and a 3-year
overall survival of 22 % [8, 9]. More commonly, however,
chemotherapy is given concurrently to overcome radio-
resistance and to improve outcomes. The leading multi-
center Radiation Therapy Oncology Group (RTOG 9610)
trial examining concurrent RI and chemotherapy showed
OS at 1 and 2 years of 40 and 15 %, respectively. In the
other RTOG study (RTOG 9911), the OS rates at 1 and
2 years were 50.2 and 25.9 %, respectively. Both trials used
a hyperfractionated, twice-daily RI schedule, to a total
dose of 60 Gy in 1.5 Gy fractions. The improvement in
outcomes in the second trial could be a result of using dif-
ferent chemotherapy agents, such as platinum-based regi-
mens, which are known to be more effective for squamous
cell carcinoma than hydroxyuria and 5-fluorouracil. More
recently, Kharofa et al. [10] published encouraging results
of their experience with a continuous course of RI and
concurrent carboplatin and paclitaxel for locally recurrent
squamous cell carcinoma of the head and neck. The
authors reported a median survival of 16 months, and
an OS of 54 % at 1 year and 31 % at 2 years.
The purpose of this study is to describe our institutional
outcomes in comparison to other published data on RI
among a similar group of patients.
Methods
We retrospectively reviewed the medical records of 30
consecutive patients who received RI for either LRR or for
in-field SP cancers between 2004 and 2012. Permission for
data abstraction was obtained from the institutional Ethics
Review Board. Three patients received brachytherapy as
their RI modality and were excluded. Thus, 27 patients
were included in the analysis.
Patients
Patients included in this retrospective study were aged
between 40 and 87 years at the time of the second diagno-
sis, with a median age of 61 years. There were 23 males
(85 %) and four females (15 %). Twenty-six patients re-
ceived RI to the head and neck area with curative intent,
whereas one patient with metastatic disease at second
presentation was re-irradiated with a palliative intent. The
RI volume was delivered to overlapping areas that had
previously been irradiated at the time of the first cancer
diagnosis. All patients had histological proof of LRR or SP
squamous cell carcinoma.
The diagnostic evaluation included a physical examin-
ation, panendoscopy with biopsies, radiologic evaluation
of the head and neck by computed tomography (CT) and/
or magnetic resonance imaging (MRI), and screening for
distant metastases using CT and/or positron emission
tomography.
For previously irradiated patients presenting with LRR
or SP tumors, surgical salvage has remained the standard
of care in our institution. In cases of unresectable lesions,
primary RI, with or without concurrent chemotherapy,
was discussed with the multidisciplinary tumor board and,
if deemed appropriate, the option was presented to the pa-
tient. Only patients with good performance status (Eastern
Cooperative Oncology Group [ECOG] performance status
of ≤2) were considered candidates for RI.
Postoperative RI was considered only if the patho-
logical features of the surgical specimen indicated a high
risk of subsequent recurrence [11, 12], such as positive
margins, lymph node metastasis with extracapsular ex-
tension, and/or multiple lymph node metastases.
Tumor
Primary head and neck tumor sites and the initial stage
of disease are reported in Table 1. The recurrence was
defined as local if the tumor recurred in the primary site
in the previous radiation field, regional if it recurred in
the previous radiation field but outside the primary site,
and locoregional if the tumor recurred in both the primary
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site and in the regional nodes. After the first course of
radiotherapy, 11 patients (41 %) had failed locally, four
(15 %) had failed regionally, 10 (37 %) had failed locore-
gionally, and two had SP (7 %).
For tumor classification, the sixth edition of the Union
Internationale Contre le Cancer (UICC) was used. De-
tailed information on staging is shown in Table 1. RI was
not necessarily given at the time of the second diagnosis;
in five patients, RI was given at the third diagnosis, as
radiotherapy was not indicated in either the first or second
courses of treatment. Of these five patients, four had
recurrences and one patient had a SP.
Salvage surgery was performed in 12 patients (44 %)
before RI and resulted in clear margins in four cases, close
or positive margins in five cases, and gross residual disease
in three cases. Concurrent chemotherapy or targeted
therapy during RI was given in 21 patients (77 %) at the
discretion of the treating physician, and it included
various agents (cisplatin, carboplatin, 5-fluorouracil, or
cetuximab). Six patients received RI alone.
Treatment
In our present study, two different schedules for RI were
used: one was similar to the RTOG bid schedule men-
tioned above, and the second consisted of a total dose of
60 Gy in 30 fractions once daily. Radiotherapy was given
concurrently with chemotherapy, usually consisting of a
platinum-based regimen, although targeted therapy such
as cetuximab was also used; this was similar to other re-
ports in the literature [13]. Radiotherapy was given with
4–6 MV photon linear accelerators using a head and
neck thermoplastic immobilization mask. Treatment was
given using either three-dimensional conformal radio-
therapy, the intensity modulated radiotherapy (IMRT)
technique, or Helical TomoTherapy, depending on the
available resources at each of the two treatment sites.
From 2004–2006, IMRT was mainly used (15 patients),
whereas starting from 2007, 11 patients were treated with
Helical TomoTherapy. The remaining patient received
three-dimensional conformal radiotherapy.
The gross tumor volume (GTV) was defined as any
macroscopically visible disease, detected by radiological
investigations or by clinical exam, in both the primary
tumor and the lymph nodes. A maximum margin of
1 cm was applied to the GTV to define the expansion to
clinical target volume (CTV). The CTV to planning target
volume margin was 5 mm in three-dimensional conformal
radiotherapy and IMRT patients, and only 3 mm in
TomoTherapy because of the image-guided radiotherapy
function that allowed better day-to-day reproducibility of
patient positioning. There was no attempt to treat any
elective lymph node area or other areas at risk outside the
CTV volume.
The most important organs at risk when RI was consid-
ered were the spinal cord, brainstem, salivary glands, optic
apparatus, and mandible. For the spinal cord and brain-
stem, the dose was also calculated to a planning organ at
risk volume (PRV), which was created by adding a 5 mm
three-dimensional margin to the organ at risk. We limited
the maximal spinal cord dose at retreatment to 20 Gy, with
a maximum PRV dose of 22 Gy; a maximal dose to the
brainstem of 20 Gy, with a maximum PRV dose of 22 Gy; a
mandible dose of 40 Gy to <50 % of its volume; and 50 %
of the parotids and salivary glands would receive no more
than 25–30 Gy. Cumulative lifetime doses after RI were
measured for all patients for whom complete information
on the first treatment was available. Two patients received
their first radiation treatment outside Canada, which
precluded the calculation of cumulative doses to target
volumes. Figure 1 illustrates how modern techniques
such as IMRT allowed for excellent target coverage, while
meeting strict constraints on the organs at risk, such as
the brainstem and spinal cord.
In our series, RI was indicated in different clinical
settings: as primary definitive treatment in 14 patients;
as adjuvant treatment postoperatively in 12 patients; and
as palliative treatment in one patient, as shown in Table 2.
Statistics
All statistical analyses were performed using SPSS soft-
ware version 10.0 (SPSS Inc, Chicago, IL, USA). Results
were expressed as actuarial values using the Kaplan–Meier
estimates. Actuarial and median survivals were calculated
from the first day of the RI course.
Results
From 2004–2012, 27 patients with LRR or SP head
and neck cancer received RI at our institution. The
median follow-up time was 24.7 months (range: 11 days–
79.3 months).
The median maximal dose delivered to the spinal cord
at retreatment was 15.5 Gy (range: 6–45 Gy), the median
maximal dose delivered to the brainstem was 20 Gy
(range: 1–63 Gy), and the median dose to the mandible
was 63 Gy (range: 5–75 Gy). It is noteworthy to realize
that these numbers represent median values of the maximal
doses, which are often received by a very small volume of
the irradiated organ. For both parotids, the mean dose was
28 Gy (range: 1–72 Gy).
Disease control
The actuarial estimates of local control were 80, 52, and
52 % at 1, 2, and 5 years, as shown in Fig. 2. The median
time to the first recurrence or the SP was 24.5 months
(range: 4.6–283 months). The median time to the third
diagnosis or second failure was 17 months (range: 3.5–
192 months).
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Response to treatment after the second course of radi-
ation was measured on either CT or MRI. The maximal
radiation response was judged 6 months after the com-
pletion of radiation therapy. Nineteen patients (70 %)
had a complete response, four patients (15 %) had a partial
response, one patient (4 %) had no response, two patients
(7 %) had progression of disease, and one patient had in-
sufficient follow-up to evaluate response to treatment.
At a median follow-up of 24.7 months, 14 patients
(52 %) had no evidence of failure, four patients (15 %)
had local failure, three (11 %) had regional failure, two
(7 %) had locoregional failure, two (7 %) had SP, and two
(7 %) had persistent disease. Five patients received their
second course of radiation at the third diagnosis. Two of
these patients were diagnosed with a SP, while the other
three had local failures. Four out of these five patients
had received high-dose radiotherapy. All four remained
locally controlled. The remaining patient with esophageal
cancer had received a palliative dose and had immediate
local progression; the patient died shortly after.
Fig. 1 a Color wash dose distribution and b dose volume histogram showing spinal cord and PRV sparing, c color wash dose distribution,
and d dose volume histogram showing brainstem and PRV sparing. PRV planning organ at risk volume
Table 2 Treatment characteristics at the time of RI
Number Percent
Surgery
Postoperative RI + systemic therapy 9 33
Postoperative RI alone 3 11
Definitive RI without surgery
RI + systemic therapy 12 45
RI alone 2 7
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Overall survival and distant metastasis
The actuarial OS rates at 1, 2, and 5 years were 77, 59,
and 57 %, respectively (Fig. 2), calculated from the first day
of the RI course. At a median follow-up of 24.7 months, 17
patients (64 %) were alive. Only three patients (11 %) devel-
oped systemic metastases; one patient developed metastasis
and died during the treatment course.
Toxicity
The National Cancer Institute Common Toxicity Criteria
for Adverse Events version 3.0 (CTCAE) was used for tox-
icity grading. Overall late grade 1–3 toxicity was reported
in 25 (93 %) of the treated patients. Details of toxicity are
presented in Tables 3 and 4. Two grade 5 toxicities oc-
curred: one as a result of carotid rupture leading to death,
and one death secondary to mucosal bleeding (in a patient
with locally recurrent disease). No brainstem or spinal
cord injuries or brain necrosis were observed.
Discussion
In our group of patients receiving high-dose RI for head
and neck LRR or SP tumors, we found excellent actuarial
local control of 52 % and OS of 57 % at 5 years. These com-
pare favorably with findings from the reported literature.
The report from the University of Texas MD Anderson
Cancer Center [14] showed a median time to progression
of 7 months and progression-free rates at 1, 2, and 5 years
of 44, 34, and 29 %, respectively. The median OS was
16 months, and the OS at 1, 3, and 5 years was 54, 31, and
20 %, respectively. Sher et al. [15] reported the results of 35
patients with recurrent head and neck cancer treated with
continuous course RI, while using platinum-based chemo-
therapy and an IMRT technique. The actuarial 2-year sur-
vival was 48 %, with a 2-year locoregional control rate of
67 % and a median OS of 1.9 years. Lee et al. [16] reported
the Memorial Sloan–Kettering Cancer Center’s experience
of 105 patients with recurrent head and neck cancer who
underwent RI with chemotherapy in 75 % of patients. An
IMRT technique was used in 70 % of patients. The 2-year
locoregional progression-free and OS rates were 42 and
37 %, respectively.
A few reasons could account for our good results. Un-
like some other studies [5, 7], all but one of our patients
received some form of IMRT, either on a linear accelerator
or on a Helical TomoTherapy unit. This has allowed for
the delivery of RI in a more conformal fashion, minimizing
acute toxicities and thus reducing treatment interruptions.
The fact that our long-term toxicity data compare favor-
ably with those of the reported literature (only three grade
4 or 5 toxicities, despite the relatively common grade 3
toxicities) again reinforces the positive effect of IMRT
Fig. 2 Local control and overall survival
Table 3 Late toxicities
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Dry mouth 21 % 52 % 7 %
Dysphagia 29 % 36 % 11 %
Trismus 28 % 31 % 7 %
Muscle fibrosis 25 % 25 % 11 %
Vascular 7 %
Loss of taste 43 % 11 %
Hearing loss 7 % 21 % 3 %
Radio-osteonecrosis 7 % 7 % 3 %
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techniques employed in our group of patients, allowing
for the delivery of radical doses of RI to tumor-bearing
volumes, with significant sparing of the critical normal
previously irradiated organs. Also, 78 % of patients in the
current report received some form of concomitant systemic
therapy, most of them with cisplatin. Our results can also
be attributed, at least partially, to careful patient selection.
In the current series, one-third of the patients had node-
negative disease at first presentation, and almost one-half
had recurrences that were only local, without lymph node
involvement, and all patients had an ECOG of ≤2.
The current series is limited by the relatively small
sample size of 27 patients. Also, given the different prac-
tices at our two affiliated institutions, our patients did
not all receive the same dose/fractionation schedule. Fif-
teen patients were treated to 60 Gy in 2 Gy fractions
once daily; however, a significant minority (six patients)
received twice-daily fractionation. In addition, 12 % of
patients did not receive concurrent systemic treatment.
On the other hand, irradiation techniques were homoge-
neous, with all but one patient receiving IMRT.
In the current series, the planning target volume based
on the GTV was re-irradiated with no attempts to treat
any elective nodal sites. This approach was similar to
that of previous series that reported on their experiences
from different centers [17–20], and which showed that
the majority of failures after RI were local at the site of
the recurrent GTVs (rGTV). In the Michigan series [21],
where RI included the rGTV with no elective neck nodal
irradiation, the authors studied 66 patients at a median
follow-up of 42 months and found that all LRRs oc-
curred within the rGTVs except for two (4 %). Sher et al.
[15] reported that 73 % of LRRs occurred within the RI
volumes in patients treated with an IMRT technique to
the rGTV alone. In the series by Popovtzer et al., [21],
71 % of patients had presented with evidence of local
failure after RI, while neck-only failures occurred in two
patients (5 %). These results confirm that recurrent local
disease continues to be a significant challenge in patients
with RI for LRR or SP tumors in the head and neck
region.
Most of the reported series currently tend to use a
continuous RI course using once-daily fractionation
schedules [22–24]. A recent report from the Beth Israel
Medical Center was published on the use of Intra-
Operative-Radiotherapy (IORT) in patients with loco-
regional recurrent head and neck cancer. Seventy-six
patients were identified who underwent treatment to a
total of 87 sites after gross-total resection. The 2-year
estimate loco-regional control was 62 % with a median
survival of 19 months and a 2-year survival rate of 42 %.
The authors concluded that IORT was well tolerated and
was associated with an encouraging local-regional disease
control and an improved overall survival [25].
Conclusions
In conclusion, our results reinforce the emerging view
in the scientific community that RI with concomitant
chemotherapy for LRR or SPs, in a region that previ-
ously received high-dose irradiation, is feasible, and it
produces good local control with chances of long-term
survival; it also features acceptable, albeit not negligible,
long-term toxicity. More importantly, clinical judgment
and careful patient selection, as well as the judicious use
of modern IMRT/image-guided radiotherapy techniques
are critical components for the safe delivery of RI. The
care of these patients requiring RI to the head and neck
region is complex and should be carried out by centers
where necessary multidisciplinary expertise and support
are available.
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